New pill targets Hard-to-Treat cancers in first human trial

NCT ID NCT06799065

First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 20 times

Summary

This early study is testing an experimental oral drug called ATX-295 in about 90 people with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants will take the pill by mouth and be closely monitored for side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

    Contact

    Contact Phone: •••-•••-••••

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.